← All trials
NCT06904183
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2025
- Primary completion
- Mar 31, 2029
- Completion date
- Mar 31, 2030
- First posted
- Apr 1, 2025
- Last posted
- Apr 29, 2025
- Enrollment
- 320
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Medical UniversityLead sponsor
- Huizhou People's Central HospitalCollaborator
- Xiamen UniversityCollaborator
- Guangzhou Medical UniversityOfficial
- First People's Hospital of FoshanCollaborator
- Guangdong Medical UniversityCollaborator
- Anqing Municipal HospitalCollaborator
- Jieyang People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.